The association of CPT-1A with these signalling pathways may be a consistent feature of HER2-positive breast cancer indicating the overall CPT-1A effect in cancer metabolism, conferring no additional predictive or prognostic effect in this group of patients. Here, ERBB2 is linked to breast cancer.